Fast-track drug approval legislation introduced

November 11, 2016 | Pamela Youngberg Dickson

The pace continues to improve, but that has not dulled legislative interest in removing barriers to FDA drug approvals. Senate Bill 3466, the Accelerating New Pharmaceutical Competition Act, (reminiscent of H.R.4918,  Speeding Access to Already Approved Pharmaceuticals Act of 2014, introduced by Rep. Steve Stivers, R-Oh.) targets the EpiPen price gouging from the supply side, thinning out the administrative obstacles that would enable the FDA to fast-track its approval of medications and medical devices that are already safely in use in other developed nations.

Continue reading →